NASDAQ : GMAB
Genmab A/S — Key statistics
Healthcare · Biotechnology · Denmark
Last price 56.49 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 33.81B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 34.92B |
| Enterprise Value | 38.59B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 59.70M |
| Shares Change (YoY) | -1.73% |
| Shares Change (QoQ) | -3.36% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 62.75% |
| Float | 55.34M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 46.01 |
| Forward PE | 37.40 |
| PS Ratio | 8.45 |
| Forward PS | 6.61 |
| PB Ratio | 5.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 40.18 |
| P/OCF Ratio | 39.19 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 48.98 |
| EV / Sales | 9.34 |
| EV / EBITDA | 28.03 |
| EV / EBIT | 28.93 |
| EV / FCF | 44.41 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.46 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | 3.78 |
| Debt / FCF | 6.07 |
| Interest Coverage | 4.96 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 14.00% |
| Return on Assets (ROA) | 8.79% |
| Return on Invested Capital (ROIC) | 12.07% |
| Return on Capital Employed (ROCE) | 11.73% |
| Weighted Average Cost of Capital (WACC) | 7.36% |
| Revenue Per Employee | $1.32M |
| Profits Per Employee | $252,645 |
| Employee Count | 3,119 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 18.58 |
Taxes
| Measure | Value |
|---|
| Income Tax | 118.00M |
| Effective Tax Rate | 13.02% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +97.10% |
| 50-Day Moving Average | 37.12 |
| 200-Day Moving Average | 30.50 |
| Relative Strength Index (RSI) | 87.58 |
| Average Volume (20 Days) | 6,600,617 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.60M |
| Short Previous Month | 6.06M |
| Short % of Shares Out | 1.09% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.67 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.13B |
| Gross Profit | 3.84B |
| Operating Income | 1.33B |
| Pretax Income | 906.00M |
| Net Income | 788.00M |
| EBITDA | 1.38B |
| EBIT | 1.33B |
| Earnings Per Share (EPS) | $1.24 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.51B |
| Total Debt | 5.27B |
| Net Cash | -3.76B |
| Net Cash Per Share | -$63.03 |
| Equity (Book Value) | 5.96B |
| Book Value Per Share | 99.78 |
| Working Capital | 1.66B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 891.00M |
| Capital Expenditures | -22.00M |
| Depreciation & Amortization | 43.00M |
| Net Borrowing | 5.36B |
| Free Cash Flow | 869.00M |
| FCF Per Share | $14.56 |
Margins
| Measure | Value |
|---|
| Gross Margin | 93.03% |
| Operating Margin | 32.29% |
| Pretax Margin | 21.93% |
| Profit Margin | 19.08% |
| EBITDA Margin | 33.33% |
| EBIT Margin | 32.29% |
| FCF Margin | 21.04% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.73% |
| Shareholder Yield | 1.73% |
| Earnings Yield | 2.17% |
| FCF Yield | 2.49% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $64.96 |
| Price Target Difference | 13.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 26.04% |
| EPS Growth Forecast (3Y) | 22.46% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.91 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |